<?xml version="1.0"?><root><article><title Title="article xml" direction="ltr">International Journal of Endocrinology and Metabolism</title><title_fa Title="Title_fa">مجله‌ي بین المللی غدد درون‌ريز و متابوليسم</title_fa><short_title Title="Short_title">Int J Endocrinol Metab</short_title><subject Title="Subject">Medical Sciences</subject><web_url Title="Web_url">http://www.ijem.org</web_url><journal_hbi_system_id Title="Journal_hbi_system_id"></journal_hbi_system_id><journal_hbi_system_user Title="Journal_hbi_system_user"></journal_hbi_system_user><journal_id_issn Title="Journal_id_issn">1726-913X</journal_id_issn><journal_id_issn_online Title="Journal_id_issn_online"></journal_id_issn_online><journal_id_pii Title="Journal_id_pii"></journal_id_pii><journal_id_doi Title="Journal_id_doi"></journal_id_doi><journal_id_iranmedex Title="Journal_id_iranmedex"></journal_id_iranmedex><journal_id_magiran Title="Journal_id_magiran"></journal_id_magiran><journal_id_sid Title="Journal_id_sid"></journal_id_sid><journal_id_nlai Title="Journal_id_nlai"></journal_id_nlai><journal_id_science Title="Journal_id_science"></journal_id_science><language Title="Language">en</language><article_id_issn_online Title="Article_id_issn_online"></article_id_issn_online><article_id_pubmed Title="Article_id_pubmed"></article_id_pubmed><article_id_pii Title="Article_id_pii"></article_id_pii><article_id_doi Title="Article_id_doi"></article_id_doi><article_id_iranmedex Title="Article_id_iranmedex"></article_id_iranmedex><article_id_magiran Title="Article_id_magiran"></article_id_magiran><article_id_sid Title="Article_id_sid"></article_id_sid><articletitle Title="ArticleTitle">Orlistat Abolishes Postprandial Lipid Peaking</articletitle><authors Title="Authors">Abejuela, ZR&lt;sup&gt;a&lt;/sup&gt;, Macaballug AG&lt;sup&gt;a&lt;/sup&gt;, Sumpio JP&lt;sup&gt;c&lt;/sup&gt;, Zacarias  MB&lt;sup&gt;b&lt;/sup&gt; and Mercado-Asis LB<author><full_name>Abejuela</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> ZR&lt;sup&gt;a&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Macaballug AG&lt;sup&gt;a&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Sumpio JP&lt;sup&gt;c&lt;/sup&gt;</full_name><suffix /><email /><code /><affiliation /></author><author><full_name> Zacarias  MB&lt;sup&gt;b&lt;/sup&gt; and Mercado-Asis LB</full_name><suffix /><email /><code /><affiliation /></author></authors><articleinstitution Title="ArticleInstitution">&lt;sup&gt;a&lt;/sup&gt;Sections of Endocrinology and Metabolism, &lt;sup&gt;b&lt;/sup&gt;Cardiology, and &lt;sup&gt;c&lt;/sup&gt;Dietary Services, University Of Santo Tomas Hospital, Manila, Philippines</articleinstitution><articlecategory Title="ArticleCategory">Original Article</articlecategory><articleabstract Title="ArticleAbstract">Postprandial hyperlipemia is associated with the development of cardiovascular disease. Orlistat is a pancreatic lipase inhibitor that reduces fat absorption from the diet by inhibition of hy-drolysis of triglycerides. Since the effect of orlis-tat on postprandial lipemia has not been fully elucidated, we studied the effect of orlistat on postprandial lipemia after a 50% oral fat chal-lenge test (OFCT). Materials and Methods: Twenty-seven healthy volunteers, aged 18-45 years old, with normal body mass index (BMI) and normal fasting lipid levels, were studied.  The control group (n=15) was given the 50% OFCT while the study/orlistat group (n=12), was given 120 mg orlistat followed by intake of the 50% OFCT.  Total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL) were determined at baseline and serially over a 6-hour period. Re-sults: In the control group, TC, TG and HDL peaked in the 4th hour. This lipid peaking was not observed in the orlistat group. Percentage change between baseline to the 4th hour values in the control vs. the study group were, respec-tively, as follows: TC = 65.80% vs. -1.60%; TG = 262.64% vs. 24.74%; and HDL = 205.26% vs. -1.43%.  The mean postprandial levels for TC, TG and LDL were well within the normal fasting cut-offs of &amp;amp;amp;amp;amp;lt;6.20 mmol/L, &amp;amp;amp;amp;amp;lt;2.26 mmol/L, and &amp;amp;amp;amp;amp;lt; 4.14 mmol/L respectively throughout the entire 6-hour study period. Conclusion: Orlistat ab-olished the peaking of TC, TG, and HDL after a 50% OFCT. Nonetheless, lipid values were main-tained within normal fasting levels in the orlistat group.</articleabstract><articlekeyword Title="ArticleKeyword">Orlistat, Lipids, Postprandial lipemia, Fatty meal, Cardiovascular disease</articlekeyword><articleruningtitle Title="ArticleRuningTitle">Orlistat abolishes lipid peaking</articleruningtitle><articlecorrespondence Title="ArticleCorrespondence">Abejuela ZR.</articlecorrespondence><articlereceivedate Title="ArticleReceiveDate">9/13/2009 12:00:00 AM</articlereceivedate><articleaccepteddate TitlePe="ArticleAcceptedDate">11/23/2009 12:00:00 AM</articleaccepteddate><articleemail Title="ArticleEmail">zabejuela@yahoo.com</articleemail><articleissuenumber Title="ArticleIssueNumber">3</articleissuenumber><articlevolumenumber Title="ArticleVolumeNumber">7</articlevolumenumber><articlestartpage Title="ArticleStartPage">179</articlestartpage><articleendpage Title="ArticleEndPage">186</articleendpage><artweb_url Title="Artweb_url">http://www.ijem.org/Default.aspx</artweb_url></article></root>